|
09 May 2013 |
Blockbuster Biologics 2012: sales are double that of 2006 driven by strong growth of recombinant antibodies
|
|
19 Mar 2012 |
The huge potential of GLP-1 receptor agonists in the diabetes market opens opportunities for technology providers and Big Pharma
|
|
24 Nov 2011 |
Blockbuster Drugs 2010: small molecules still dominating, but biologics strongly emerging
|
|
26 Oct 2011 |
Fierce Competition Requires Precision in Meeting the Needs of the Coagulation Factor Market
|
|
16 Sep 2011 |
Antibody-Drug Conjugates 2011 - real breakthrough still to come
|
|
07 Mar 2011 |
Biologics Sales in 2010 exceeded US$ 100 bln
|
|
08 Sep 2010 |
The Product Portfolio Strategy as Decisive Force in Forming the Future Coagulation Factor Market
|
|
14 Aug 2009 |
Changes ahead in the coagulation factor market by new entrants and technologies
|
|
11 Nov 2008 |
Trends in the diabetes drug pipeline 2008
|
|
28 Oct 2008 |
The future of human insulin: tailored and oral
|
|
07 Oct 2008 |
Human growth hormone (hGH): biosimilar pricing is not enough, convenience will mandate
|
|
10 Sep 2008 |
Takeda reigns supreme among Japanese pharma companies
|
|
28 Aug 2008 |
Emerging diabetes drugs consider beta cell mass and function as an important target
|
|
12 Aug 2008 |
The third generation of TPO mimetics are again biologics
|
|
07 Aug 2008 |
The changing marketplace of antithrombotics: better than cheaper?
|
|
23 Jul 2008 |
Erythropoietins: the shift from biosimilars to “more for less” ESAs
|
|
28 Mar 2008 |
Cancer and TNF antibodies boost Biologics Sales in 2007
|
|
11 Feb 2008 |
2008 is a decisive year for the validation of the asthma target interleukin-13
|
|
23 Jul 2007 |
114 Blockbuster Drugs Accounted for 2006 Sales of US$ 233.7 bln
|
|
30 May 2007 |
The imminent change of the antithrombotics market
|
|
02 May 2007 |
Up and down with cholesterol management
|
|
25 Apr 2007 |
Beyond biogenerics: the real threats for therapeutic proteins
|
|
15 Mar 2007 |
La Merie and PharmaPlus team up to provide No-Frills business intelligence solutions
|
|
08 Mar 2007 |
Weight management is not enough for cannabinoid type 1 (CB1) receptor antagonists to become a commercial success
|
|
01 Mar 2007 |
The new class of dipeptidyl peptidase IV (DPP-IV) inhibitors has one clear leader and many followers
|
